perflubron has been researched along with Atherosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Chen, L; Liang, R; Wei, J | 1 |
| Guo, Q; Jing, F; Li, X; Sui, Z; Sun, J; Xu, W | 1 |
1 review(s) available for perflubron and Atherosclerosis
| Article | Year |
|---|---|
Perfluorooctylbromide nanoparticles for ultrasound imaging and drug delivery.
Topics: Animals; Atherosclerosis; Contrast Media; Drug Carriers; Drug Delivery Systems; Fluorocarbons; Humans; Hydrocarbons, Brominated; Nanoparticles; Neoplasms; Ultrasonography | 2018 |
1 other study(ies) available for perflubron and Atherosclerosis
| Article | Year |
|---|---|
Ultrasound and magnetic resonance molecular imaging of atherosclerotic neovasculature with perfluorocarbon magnetic nanocapsules targeted against vascular endothelial growth factor receptor 2 in rats.
Topics: Animals; Antibodies; Aorta; Atherosclerosis; Cattle; Contrast Media; Disease Models, Animal; Drug Compounding; Endothelial Cells; Ferric Compounds; Fluorocarbons; Hydrocarbons, Brominated; Magnetic Resonance Imaging; Male; Nanocapsules; Neovascularization, Pathologic; Plaque, Atherosclerotic; Primary Cell Culture; Rats; Rats, Sprague-Dawley; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2017 |